New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 28, 2014
11:18 EDTCROX, PBYI, CRUS, CMG, MLNX, INO, QLIK, DECK, HLF, INFNOptions with decreasing implied volatility
Options with decreasing implied volatility: INO PBYI HLF MLNX CROX DECK CMG INFN QLIK CRUS
News For INO;PBYI;HLF;MLNX;CROX;DECK;CMG;INFN;QLIK;CRUS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
April 22, 2015
05:50 EDTCMGStocks with implied volatility movement; CMG IP
Stocks with implied volatility movement; Chipotle (CMG) 37, International Paper (IP) 28 according to iVolatility.
April 21, 2015
19:06 EDTINFN, CMGOn The Fly: After Hours Movers
Subscribe for More Information
17:18 EDTINFNInfinera sees new financial model in effect in 2016 after Transmode acquisition
Subscribe for More Information
17:16 EDTINFNInfinera sees Q2 EPS 16c plus or minus 'a couple of pennies', consensus 12c
Subscribe for More Information
17:12 EDTINFNInfinera sees Transmode acquisition accretive to FY16 EPS
Subscribe for More Information
16:20 EDTINFNInfinera reports Q1 EPS 16c, consensus 11c
Reports Q1 revenue $186.9M, consensus $186.09M. GAAP gross margin for the quarter was 47.2%, compared to 45.3% in the fourth quarter of 2014 and 40.9% in the first quarter of 2014. Non-GAAP gross margin for the quarter was 47.8%, compared to 46.1% in the fourth quarter of 2014 and 41.8% in the first quarter of 2014.
16:14 EDTCMGChipotle exploring options to increase pork supply
Subscribe for More Information
16:03 EDTCMGChipotle sees FY15 comp restaurant sales growing low-to-mid single digit
Subscribe for More Information
16:02 EDTCMGChipotle reports Q1 EPS $3.88, consensus $3.66
Subscribe for More Information
15:28 EDTINFN, CMGNotable companies reporting after market close
Subscribe for More Information
14:00 EDTMLNXOptions with decreasing implied volatility
Options with decreasing implied volatility: NFLX MLNX XON WUBA MEMP BMRN FTNT BPT SNDK
13:52 EDTCMGChipotle April weekly 697 straddle priced for 6.9% movement into Q1
Subscribe for More Information
13:47 EDTCMGChipotle technical view ahead of earnings
Subscribe for More Information
09:22 EDTMLNXOn The Fly: Pre-market Movers
Subscribe for More Information
08:41 EDTCMGOptions expected to be active
Options expected to be active: UA TEVA PRGO MYL UTX QCOM VMW HOG CMG IBM VZ
07:07 EDTMLNXMellanox sees Q2 revenue $155M-$160M, consensus $149.31M
Sees Q2 non-GAAP gross margin 71%-72%.
07:06 EDTMLNXMellanox reports Q1 adjusted EPS 60c, consensus 48c
Subscribe for More Information
07:05 EDTMLNXMellanox announces retirement of Roni Ashuri, COO Shai Cohen
Subscribe for More Information
06:52 EDTCMGChipotle volatility elevated into Q1 and outlook
Subscribe for More Information
05:33 EDTINOInovio, Roche initiate clinical trial for DNA immunotherapy to treat HCB
Inovio Pharmaceuticals (INO) announced that it has initiated a Phase I trial to evaluate Inovio's DNA immunotherapy in patients who are chronically infected with hepatitis B. In 2013, Roche (RHHBY) and Inovio entered into a partnership to co-develop and commercialize Inovio's hepatitis B immunotherapy. This trial initiation triggers a $3M milestone payment from Roche to Inovio. This phase I, randomized, open-label, active-controlled, dose escalation study will evaluate the safety, tolerability, and immunogenicity of Inovio's hepatitis B immunotherapy, INO-1800, alone or in combination with INO-9112, Inovio's IL-12-based immune activator. This international study will enroll patients in the United States and Asia Pacific region with a primary endpoint of safety and tolerability of the therapy. The secondary endpoints will evaluate the cellular and humoral immune response to INO-1800 and investigate the therapy's effect on several viral and antiviral parameters. All trial subjects are also medicated with standard-of-care antiviral therapies.
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use